Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a genetic test and MRI team up to improve prostate cancer treatment choices?

NCT ID NCT04541030

Ongoing Knowledge-focused Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 9 times

Summary

This study looks at whether combining a genetic test called the Genomic Prostate Score (GPS) with MRI scans can help doctors better choose men with prostate cancer for focal therapy, which treats only the cancerous part of the prostate. Researchers will analyze data and tissue samples from 241 men who previously had prostate surgery. The goal is to see if the GPS score, along with MRI results, can predict which cancers are more aggressive and need broader treatment.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Oncotype DX Genomic Prostate Score (GPS) test
What this could lead to
If successful, this could help doctors more accurately choose which men with prostate cancer are good candidates for focal therapy, potentially reducing side effects from more aggressive treatments.
What could go wrong
This is a retrospective study using existing data, not a new treatment trial. The GPS test is already in use, so the main question is how well it works with MRI, not a breakthrough discovery.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

  • National Cancer Institute (NCI)

    Bethesda, Maryland, 20892, United States

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35294, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.